Overview

A Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of TransCon CNP Administered Once Weekly in Prepubertal Children With Achondroplasia

Status:
Enrolling by invitation
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
The trial is a multicenter, double-blind, randomized, placebo-controlled, dose escalation trial of weekly TransCon CNP administered subcutaneously in prepubertal children 2 to 10 years old, inclusive, with Achondroplasia.
Phase:
Phase 2
Details
Lead Sponsor:
Ascendis Pharma A/S